HemoShear Therapeutics

HemoShear works with pharmaceutical companies to identify and validate new drug targets and to de-risk drug discovery and development decisions. HemoShear’s proprietary technology combines important physiological parameters to recreate in vivo biology on the bench top and provide insights that are far more predictive of human response than current methods used in the laboratory.

UVA Founders: Brett R. Blackman, Ph.D.; Brian R. Wamhoff, Ph.D.